Search

Your search keyword '"Finegold SM"' showing total 481 results

Search Constraints

Start Over You searched for: Author "Finegold SM" Remove constraint Author: "Finegold SM"
481 results on '"Finegold SM"'

Search Results

6. Treatment of Anaerobic Infections

7. Prebiotic Potential and Chemical Composition of Seven Culinary Spice Extracts.

8. Detection of Clostridium perfringens toxin genes in the gut microbiota of autistic children.

9. Pomegranate ellagitannins stimulate the growth of Akkermansia muciniphila in vivo.

10. Response to Maja Rupnik.

11. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938.

12. Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis.

13. Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study.

14. Pomegranate ellagitannins stimulate growth of gut bacteria in vitro: Implications for prebiotic and metabolic effects.

15. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers.

16. Antimicrobial Activity of Pomegranate and Green Tea Extract on Propionibacterium Acnes, Propionibacterium Granulosum, Staphylococcus Aureus and Staphylococcus Epidermidis.

17. Reclassification of Ruminococcus obeum as Blautia obeum comb. nov.

18. In vitro study of the prebiotic xylooligosaccharide (XOS) on the growth of Bifidobacterium spp and Lactobacillus spp.

19. Pomegranate extract exhibits in vitro activity against Clostridium difficile.

20. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota.

21. Genes Encoding Toxin of Clostridium difficile in Children with and without Diarrhea.

22. Single nucleotide polymorphisms are randomly dispersed and mostly synonymous in partial rpoB and cpn60 genes of Campylobacter showae human isolates.

23. Peptoniphilus duerdenii sp. nov. and Peptoniphilus koenoeneniae sp. nov., isolated from human clinical specimens.

24. Occurrence and antimicrobial susceptibility of Porphyromonas spp. and Fusobacterium spp. in dogs with and without periodontitis.

25. Microbiology of regressive autism.

26. Corynebacterium pyruviciproducens promotes the production of ovalbumin specific antibody via stimulating dendritic cell differentiation and up-regulating Th2 biased immune response.

27. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism.

28. Detection of Porphyromonas gulae from subgingival biofilms of dogs with and without periodontitis.

29. Desulfovibrio species are potentially important in regressive autism.

30. Application of quantitative real-time PCR for rapid identification of Bacteroides fragilis group and related organisms in human wound samples.

31. Phosphorylated dihydroceramides from common human bacteria are recovered in human tissues.

32. Quantitative detection of enterotoxigenic Bacteroides fragilis subtypes isolated from children with and without diarrhea.

33. Pyrosequencing study of fecal microflora of autistic and control children.

34. Corynebacterium pyruviciproducens sp. nov., a pyruvic acid producer.

35. Gemella asaccharolytica sp. nov., isolated from human clinical specimens.

36. Murdochiella asaccharolytica gen. nov., sp. nov., a Gram-stain-positive, anaerobic coccus isolated from human wound specimens.

37. Characterization of Slackia exigua isolated from human wound infections, including abscesses of intestinal origin.

38. Innate immune recognition of, and response to, Clostridium sordellii.

39. Phenotypic and molecular characterization of Solobacterium moorei isolates from patients with wound infection.

40. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

41. Mobilization and prevalence of a Fusobacterial plasmid.

42. Approaches to the study of the systematics of anaerobic, gram-negative, non-sporeforming rods: current status and perspectives.

43. Evaluation of genotypic and phenotypic methods for differentiation of the members of the Anginosus group streptococci.

44. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.

45. Porphyromonas bennonis sp. nov., isolated from human clinical specimens.

46. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

47. Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydrogenotrophica comb. nov., Blautia luti comb. nov., Blautia producta comb. nov., Blautia schinkii comb. nov. and description of Blautia wexlerae sp. nov., isolated from human faeces.

48. Therapy and epidemiology of autism--clostridial spores as key elements.

49. Clostridium tertium isolated from gas gangrene wound; misidentified as Lactobacillus spp initially due to aerotolerant feature.

50. Peptoniphilus gorbachii sp. nov., Peptoniphilus olsenii sp. nov., and Anaerococcus murdochii sp. nov. isolated from clinical specimens of human origin.

Catalog

Books, media, physical & digital resources